Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to UY31237ApriorityCriticalpatent/UY31237A1/en
Publication of UY31237A1publicationCriticalpatent/UY31237A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invencion se refiere a nuevos derivados de tomaimicina que comprenden un ligante.También se refiere a las moléculas de conjugado que comprenden uno o más de dichos derivados de tamaimicina unidos mediante enlaces covalentes a un agente de union a la célula por un grupo de enlace que está presente en el ligante del derivado de tomaimicina. También se refiere a la preparacion de los derivados de tomaimicina y de las moléculas de conjugado.The invention relates to novel tomaimycin derivatives comprising a binder. It also relates to conjugate molecules comprising one or more of said tamaimycin derivatives linked by covalent bonds to a cell binding agent by a linking group that It is present in the binder of the tomaimycin derivative. It also refers to the preparation of tomaimycin derivatives and conjugate molecules.
UY31237A2008-07-172008-07-17
CYTOTOXIC AGENTS UNDERSTANDING NEW TOMAIMYCIN DERIVATIVES AND THERAPEUTIC USE
UY31237A1
(en)
Leptomycin derived compound; conjugate comprising cell binding agent bound to one or more of said derivatives; pharmaceutical compositions comprising said derivative or conjugate; useful in the treatment of cancer; process of preparing a compound or a conjugate of a leptomycin derivative.